Advertisement
IOVA vs NCNA
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IOVA is a Hold and NCNA is a StrongBuy.
Aroon Indicator for IOVA shows an upward move is likely
IOVA's Aroon Indicator triggered a bullish signal on October 08, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 155 similar instances where the Aroon Indicator showed a similar pattern. In 138 of the 155 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 19, 2026. You may want to consider a long position or call options on IOVA as a result. In 80 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
Following a +9.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where IOVA advanced for three days, in 201 of 254 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The 10-day RSI Indicator for IOVA moved out of overbought territory on October 16, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 25 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Moving Average Convergence Divergence Histogram (MACD) for IOVA turned negative on October 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 35 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IOVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
IOVA broke above its upper Bollinger Band on September 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 15 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.160) is normal, around the industry mean (2.988). P/E Ratio (-21.188) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.370) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (12.484) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. IOVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IOVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
NCNA's RSI Oscillator remains in oversold zone for 4 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +7.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where NCNA advanced for three days, in 164 of 209 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
NCNA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on NCNA as a result. In 87 of 93 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NCNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NCNA entered a downward trend on October 07, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.198) is normal, around the industry mean (2.988). P/E Ratio (0.019) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 88 (best 1 - 100 worst), indicating slightly worse than average price growth. NCNA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NCNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
IOVA | NCNA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 84 | 52 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | 50 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 97 | 98 | |
PRICE GROWTH RATING 1..100 | 34 | 88 | |
P/E GROWTH RATING 1..100 | 98 | 4 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
IOVA's Valuation (15) in the Biotechnology industry is somewhat better than the same rating for NCNA (50). This means that IOVA’s stock grew somewhat faster than NCNA’s over the last 12 months.
IOVA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as NCNA (100). This means that IOVA’s stock grew similarly to NCNA’s over the last 12 months.
IOVA's SMR Rating (97) in the Biotechnology industry is in the same range as NCNA (98). This means that IOVA’s stock grew similarly to NCNA’s over the last 12 months.
IOVA's Price Growth Rating (34) in the Biotechnology industry is somewhat better than the same rating for NCNA (88). This means that IOVA’s stock grew somewhat faster than NCNA’s over the last 12 months.
NCNA's P/E Growth Rating (4) in the Biotechnology industry is significantly better than the same rating for IOVA (98). This means that NCNA’s stock grew significantly faster than IOVA’s over the last 12 months.
| IOVA | NCNA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | 2 days ago 89% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 77% |
| Momentum ODDS (%) | 2 days ago 88% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 78% | N/A |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| Advances ODDS (%) | 3 days ago 79% | 16 days ago 78% |
| Declines ODDS (%) | 9 days ago 87% | 4 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 73% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 87% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IOVA’s FA Score shows that 1 FA rating(s) are green while NCNA’s FA Score has 1 green FA rating(s).
- IOVA’s FA Score: 1 green, 4 red.
- NCNA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IOVA’s TA Score shows that 3 TA indicator(s) are bullish while NCNA’s TA Score has 4 bullish TA indicator(s).
- IOVA’s TA Score: 3 bullish, 5 bearish.
- NCNA’s TA Score: 4 bullish, 3 bearish.
Price Growth
IOVA (@Biotechnology) experienced а +2.89% price change this week, while NCNA (@Biotechnology) price change was -8.37% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -1.10%. For the same industry, the average monthly price growth was -18.18%, and the average quarterly price growth was -15.20%.
Reported Earning Dates
IOVA is expected to report earnings on Nov 05, 2026.
NCNA is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (-1.10% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
NCNA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NCNA has been closely correlated with TAOX. These tickers have moved in lockstep 92% of the time. This A.I.-generated data suggests there is a high statistical probability that if NCNA jumps, then TAOX could also see price increases.
| Ticker / NAME | Correlation To NCNA | 1D Price Change % | ||
|---|---|---|---|---|
| NCNA | 100% | -2.94% | ||
| TAOX - NCNA | 92% Closely correlated | +4.88% | ||
| PALI - NCNA | 81% Closely correlated | -2.10% | ||
| PLX - NCNA | 34% Loosely correlated | -2.65% | ||
| IOVA - NCNA | 34% Loosely correlated | -1.62% | ||
| DMRA - NCNA | 31% Poorly correlated | +4.16% | ||
More | ||||